Zealand Pharma President of US Operations on first launch: Timing was our most important goal
Zealand Pharma has started to launch its hypoglycemia treatment Zegalogue in the US. According to the president of the firm's US operations, this is a crucial time as Americans start returning to schools and the covid-19 pandemic has led the company to invest significantly in digital sales and promotion opportunites.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
By launching low blood sugar treatment Zegalogue on the US market, Zealand Pharma is marking its transition from development company to commercial biotech company. Although it was established in 1998, the firm had never sent its own drug to market until last week.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk wants to innovate in new ways to find cures
For subscribers
Zealand Pharma sends blood sugar drug to US market
For subscribers
Three global giants consider vaccine production in Denmark
For subscribers
